• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Refining precision prognostics in multiple myeloma: loss of miR-221/222 cluster in CD138+ plasma cells results in short-term progression and worse treatment outcome

by | Mar 16, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Myeloma Awareness Month and Acknowledging Early Symptoms of The Disease

by | Mar 14, 2025 | Uncategorized

Source: CureToday articles Dr. Joseph Mikhael discusses the overlooked symptoms of multiple myeloma in honor of Myeloma Awareness Month. Read More

Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis

by | Mar 14, 2025 | Publications

Blood Cancer J. 2025 Mar 13;15(1):37. doi: 10.1038/s41408-025-01253-5. ABSTRACT The treatment landscape for transplant-eligible patients with newly diagnosed multiple myeloma (TE-NDMM) has evolved with the introduction of daratumumab-based quadruplet regimens. Adding...

Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis

by | Mar 13, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Correction: Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection

by | Mar 13, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More
« Older Entries
Next Entries »

Recent Content

  • The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review
  • (no title)
  • Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes
  • (no title)
  • Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis
  • (no title)
  • Peroxiredoxins as novel indicators in multiple myeloma associated with ferroptosis and immune infiltration
  • (no title)
  • (no title)
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT